Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...
Unitaid awards Medincell US$6m to fight malaria
The funding commitment for MedinCell Corp’es reformulation of the antipararsitic ivermectin comes after great progress in malaria vaccines: The...
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
AstraZeneca to take over Fusion Therapeutics Inc
Fusion Pharmaceuticals Inc‘s acquisition for US$2bn upfront marks a major step forward in AstraZeneca delivering on its ambition to transform cancer...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Gut bacteria seed autoimmunity-inducers
A unique mechanism, reported by an Irish-French research team underscores an emerging theme in microbiome research: that disruptions to gut bacteria...
Vidac Pharma Holding plc reports preclinical proof of principle
Vidac Pharma Holdings plc will report promising results for its cancer drug candidate VDA-1275 in multiple mouse cancer and human cellular...